DK3405196T3 - Nye substituerede cyanoindolinderivater som nik-inhibitorer - Google Patents

Nye substituerede cyanoindolinderivater som nik-inhibitorer Download PDF

Info

Publication number
DK3405196T3
DK3405196T3 DK17701110.3T DK17701110T DK3405196T3 DK 3405196 T3 DK3405196 T3 DK 3405196T3 DK 17701110 T DK17701110 T DK 17701110T DK 3405196 T3 DK3405196 T3 DK 3405196T3
Authority
DK
Denmark
Prior art keywords
substituerede
cyanoindolinderivater
inhibitorer
nye
nik
Prior art date
Application number
DK17701110.3T
Other languages
Danish (da)
English (en)
Inventor
Ian Stansfield
Olivier Alexis Georges Querolle
Virginie Sophie Poncelet
Gerhard Max Gross
Edgar Jacoby
Lieven Meerpoel
Janusz Jozef Kulagowski
Calum Macleod
Samuel Edward Mann
Simon Richard Green
George Hynd
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK3405196T3 publication Critical patent/DK3405196T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/535Organo-phosphoranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK17701110.3T 2016-01-22 2017-01-20 Nye substituerede cyanoindolinderivater som nik-inhibitorer DK3405196T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152416 2016-01-22
EP16159651 2016-03-10
PCT/EP2017/051150 WO2017125530A1 (en) 2016-01-22 2017-01-20 New substituted cyanoindoline derivatives as nik inhibitors

Publications (1)

Publication Number Publication Date
DK3405196T3 true DK3405196T3 (en) 2020-03-09

Family

ID=57868252

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17701110.3T DK3405196T3 (en) 2016-01-22 2017-01-20 Nye substituerede cyanoindolinderivater som nik-inhibitorer

Country Status (20)

Country Link
US (1) US11180487B2 (https=)
EP (1) EP3405196B1 (https=)
JP (1) JP6910359B2 (https=)
KR (1) KR102784966B1 (https=)
CN (1) CN108697710B (https=)
AU (1) AU2017209935B2 (https=)
BR (1) BR112018014675B1 (https=)
CA (1) CA3011880A1 (https=)
DK (1) DK3405196T3 (https=)
ES (1) ES2775449T3 (https=)
HR (1) HRP20200133T1 (https=)
HU (1) HUE047684T2 (https=)
IL (1) IL260500B (https=)
LT (1) LT3405196T (https=)
MX (1) MX2018008974A (https=)
PH (1) PH12018501567A1 (https=)
SI (1) SI3405196T1 (https=)
TW (1) TWI739783B (https=)
WO (1) WO2017125530A1 (https=)
ZA (1) ZA201804688B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としての新たな置換されたシアノインドリン誘導体
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
EP3492462B1 (en) 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
KR102704889B1 (ko) * 2017-09-30 2024-09-10 하이헤 바이오파마 컴패니 리미티드 Erk 키나제 억제 활성을 갖는 화합물 및 그의 용도
TW202045008A (zh) 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
KR20210125558A (ko) * 2019-04-02 2021-10-18 하이노바 파마슈티컬스 인코포레이티드 방향족 아민계 화합물 및 이의 ar 및 brd4 이중 억제제 및 조절제의 제조에서의 용도
UA130430C2 (uk) 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
US20240285599A1 (en) * 2021-08-23 2024-08-29 Osaka University Mature-Hepatocyte Transdifferentiation Suppressing Composition
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
CA2441733A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
JP2011525915A (ja) * 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
PE20130774A1 (es) 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
MX2013011908A (es) 2011-04-12 2014-03-27 Alzheimer S Inst Of America Inc Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
CN110229142A (zh) 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
CA2946164A1 (en) 2014-05-22 2015-11-26 The University Of Sydney Omega-3 analogues
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
NZ729618A (en) 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CN106928216A (zh) 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ.ベー. Nik阻害剤としての新たな置換されたシアノインドリン誘導体
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors

Also Published As

Publication number Publication date
US11180487B2 (en) 2021-11-23
BR112018014675A2 (pt) 2018-12-11
ZA201804688B (en) 2022-03-30
JP2019504067A (ja) 2019-02-14
CN108697710B (zh) 2022-02-18
KR102784966B1 (ko) 2025-03-20
JP6910359B2 (ja) 2021-07-28
WO2017125530A1 (en) 2017-07-27
ES2775449T3 (es) 2020-07-27
KR20180100441A (ko) 2018-09-10
IL260500B (en) 2021-01-31
HRP20200133T1 (hr) 2020-05-15
SI3405196T1 (sl) 2020-03-31
BR112018014675B1 (pt) 2023-12-19
US20210087182A1 (en) 2021-03-25
HUE047684T2 (hu) 2020-05-28
AU2017209935A1 (en) 2018-08-09
EP3405196B1 (en) 2019-12-04
AU2017209935B2 (en) 2021-04-01
EP3405196A1 (en) 2018-11-28
MX2018008974A (es) 2018-11-09
LT3405196T (lt) 2020-02-25
CA3011880A1 (en) 2017-07-27
CN108697710A (zh) 2018-10-23
TW201728577A (zh) 2017-08-16
TWI739783B (zh) 2021-09-21
PH12018501567A1 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
DK3512547T3 (en) Anti-pd-1-antistoffer
DK3092236T3 (en) Nye glutaminaseinhibitorer
DK3504696T3 (en) Optisk kommunikativt batteristyringssystem
DK3482386T3 (en) Patientsimulator
AU201616677S (en) Cylindres
DK3405196T3 (en) Nye substituerede cyanoindolinderivater som nik-inhibitorer
DK3438253T3 (en) Phytasemutant
DK3468998T3 (en) Anti-tnfrsf25-antistoffer
DK3544712T3 (en) Filtersystem
EP3370135A4 (en) Operation device
DK3538786T3 (en) Friktionsmateriale
DK3386951T3 (en) Phenylderivater som cannabinoidreceptor-2-agonister
DK3270751T3 (en) Foodprocessor
AU201710564S (en) Bookrack
DK3551631T3 (en) Non-peptid oxytocin-receptoragonister
DK3440392T3 (en) Styreapparat
EP3275377A4 (en) Operation field-securing device
EP3144551A4 (en) Movement device
GB201410005D0 (en) Cajon
GB201609686D0 (en) Devices
PL3469691T3 (pl) Konfiguracja szyku halbacha
EP3352063A4 (en) ACTUATING DEVICE
EP3260213A4 (en) Roll-molding device
EP3324263A4 (en) Operation device
DK3430092T3 (en) Coatingsystem